Instructions for MOVIPREP (Sodium sulfate, Macrogol) Powder
Release Form
Powder for cooking solution for intake
Description:
Powder for preparation of solution for injection from white to yellow color with characteristic odor of lemon (sashe A).
1 Sasha A
macrogol-3350 100.00 g
sodium sulfate, waterless 7.500 g
sodium chloride 2.691 g
potassium chloride 1.015 g
Auxiliary substances: aspartam - 0.233 g, potassium acesulpham - 0.117 g, lemon flavor V3938-1 N1 - 0.340 g.
Powder for preparation of solution for injection from white to light brown (Sasha B).
1 Sash B
ascorbic acid 4.700 g
Sodium ascorbatant 5.900 g
111.896 g + 10.600 g - Sasha A (1) and Sasha B (1) - polyethylene (2) bags - cardboard.
ATX codes
A06AD65 Macrogol in combination with other drugs MOVIPREP
Pharmacological groups / Group membership
Weak drug MOVIPREP
Active substance:
- ascorbic acid
- sodium chloride
- potassium chloride
- sodium ascorbat
- macrogol 3350
- sodium sulfate
Pharmacy Group:
Weak remedy
Retention Terms
The drug MOVIPREP should be stored in a place not accessible to children at a temperature not exceeding 25°C.
Shelf life
Shelf life - 3 years.
Store the recovered solution at a temperature not exceeding 8°C. Shelf life - 24 h.
Pharmaceuticals
Pharmacodynamics:
The oral treatment of electrolyte solution based on macrogola causes moderate diarrhea, which results in the rapid emptying of the contents of the colon.
Macrogol-3350, sodium sulfate and ascorbic acid have osmotic effect which causes a laxative effect.
Macrogol-3350 increases the volume of calves, which leads to the strengthening of the peristaltic of the intestine.
The electrolytes that are part of the drug MOVIPREP, as well as the additional liquid treatment, prevent the water-electrolyte balance.
Indications:
Preparation for diagnostic studies (e.g. endoscopic, x-ray, and other intestinal studies) and operational interventions requiring bowel emptying.
Method of application, course and dosage:
An important intestinal preparation process, which includes 3 stages, must be completed before diagnostic studies (e.g. endoscopic, x-ray and other intestinal studies) and surgery are carried out:
1. Adherence to special diet.
2. Selection of the drug MOVIPREP treatment scheme depending on the time of the investigation or operation.
3. Carrying out the process of intestinal purification with the help of the drug MOVIPREP
Detailed information on each step is shown below.
1. Adherence to special diet
It is important to observe a special diet 3 days before the study or operation:
Allowed Not Allowed
All protein food:
- cooked meat and poultry (other than sausage products);
- non-fat fish varieties;
- non-fat sour-dairy products;
- eggs. All plant food:
- vegetables;
- fruit;
- berries;
- green;
- cereals;
- nuts;
- Kashi;
- bread.
Jele, sugar, honey.
Liquids:
- transparent broth;
- milk-free tea;
- milk-free coffee;
- Compots without berries;
- juice without flesh;
- soft uncolored drinks;
- water. Liquids:
- colored juices;
- alcohol;
- carbonated drinks.
All non-Allow products
Time of the study The scheme of taking the drug MOVIPREP
08:00-10:00
Dietary intake 3 days before the study: according to the list of allowed products and liquids.
Dietary intake 2 days before the study: according to the list of allowed products and liquids.
Nutrition on the eve of the day of study:
breakfast: according to the list of allowed products and liquids;
lunch and dinner: only allowed transparent liquids. One-stage evening circuit*
The day before the study:
19:00-20:00 take the first liter of the drug solution;
21:00-22:00 take the second liter of the drug solution.
After every liter of the drug you take, you need to drink 500 ml of the permitted liquid.
10:00-14:00
Dietary intake 3 days before the study: according to the list of allowed products and liquids.
Dietary intake 2 days before the study: according to the list of allowed products and liquids.
Nutrition on the eve of the day of study:
breakfast and light lunch until 13:00: according to the list of allowed products and liquids;
dinner: only allowed transparent liquids. Two-step diagram*
The day before the study:
20:00-21:00 take the first liter of the drug solution.
Research day:
06:00-07:00 take the second liter of the drug MOVIPREP solution.
After every liter of the drug you take, you need to drink 500 ml of the permitted liquid.
14:00-19:00
Dietary intake 3 days before the study: according to the list of allowed products and liquids.
Dietary intake 2 days before the study: according to the list of allowed products and liquids.
Nutrition on the eve of the day of study:
- breakfast, lunch and light dinner until 18:00: according to the list of allowed products.
On the day of the colonoscopy in the morning: only allowed transparent liquids. One-stage morning circuit*
Research day:
08:00-09:00 take the first liter of the drug MOVIPREP solution;
10:00-11:00 take the second liter of the drug solution.
After every liter of the drug MOVIPREP you take, you need to drink 500 ml of the permitted liquid.
* If necessary, the time of taking Movi drug MOVIPREP
In the two-stage dosing scheme, the treatment of MOVIPREP and other liquids (according to the list of authorized - see above) must be stopped not less than 1 hour, but not more than 4 hours before the start of the procedure.
In the case of one-stage morning and one-stage evening dosage schemes®, the use of the drug MOVIPREP must be stopped not less than 2 hours, but not more than 4 hours before the beginning of the procedure, and the use of other liquids (according to the list of authorized - see above) must be stopped not less than 1 hour, but not more 4 hours before the procedure begin
The test of readiness for diagnostic examination or operational intervention is the appearance of a liquid transparent or almost transparent, slightly colored chair.
When taking a solution of the drug MOVIPREP at home it is necessary to take into account the appropriate time interval for traveling to the clinic for carrying out the procedure.
A frequent liquid chair usually occurs within 1 hour from the start of each liter of the treatment of MOVIPREP and usually ends in 1-2 hours. During the period of treatment the rate of defection may increase to 12-15 times.
If a patient takes any medication, he should tell the treating doctor before taking MOVIPREP.
Specific features of application in individual groups of patients
Care should be taken when taking this drug in patients with severe kidney failure (CC<30 ml/min).
Patients with kidney impairment or patients with a potassium-controlled diet should be aware that the drug contains 14.2 mmol of potassium per 1 liter of solution.
Overdose:
Symptoms: Severe diarrhea, which may cause a disturbance in the hydroelectric balance.
Treatment: Usually it is enough to eat a large amount of liquid, preferably fruit juices. If necessary - infusion solutions for water-electrolyte balance restoration.
Drug Interaction:
Diarrhea caused by the use of the drug MOVIPREP may lead to disrupted absorption of other concurrent drugs. Medicines taken orally within one hour of the drug's laxative effects (e.g. oral contraceptives) can be derived from the LCT without absorption.
Use in pregnancy and breastfeeding
The experience of using Mowiprep ® during pregnancy and during breastfeeding is limited. MOVIPREP should be used only if the intended benefit for the mother exceeds the potential risk for the fetus or child (medical advice is needed).
Side Action
Diarrhea is an expected effect when preparing the intestine. Due to the nature of the drug's MOVIPREP effects during preparation of the intestine for the procedure, unwanted effects are observed in most patients. Despite some differences in the specific cases, the most common unwanted effects are: nausea, vomiting, swelling of the abdomen, abdominal pain, anus irritation and sleep disorders. Diarrhea and/or vomiting can lead to dehydration
As with other products, which include a macrogola, various allergic reactions are possible, including rash, brick, itching, dispnoe, Quinke's edema and anaphylactic shock.
Undesirable effects are classified according to frequency of occurrence: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/1000, <1/1,000), very rarely (<1/10,000), the frequency is unknown (it is impossible to estimate based on the data obtained).
From the immune system: The frequency is unknown - allergic reactions, including anaphylactic reactions, dispnoe and skin reactions.
Mental health disorders: Often - sleep disorders.
On the side of the nervous system: often - dizziness, headache; Frequency unknown - convulsions associated with acute hypoonatryemia.
From metabolism and nutrition: frequency unknown - dehydration